NUEDEXTA (Avanir Pharmaceuticals, Inc.)


Welcome to the PulseAid listing for the NUEDEXTA drug offered from Avanir Pharmaceuticals, Inc.. This Uncompetitive N-methyl-D-aspartate Receptor Antagonist [EPC],Sigma-1 Agonist [EPC],Uncompetitive NMDA Receptor Antagonists [MoA],Sigma-1 Receptor Agonists [MoA],Antiarrhythmic [EPC],Cytochrome P450 2D6 Inhibitor [EPC],Cytochrome P450 2D6 Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: Avanir Pharmaceuticals, Inc.
NON-PROPRIETARY NAME: dextromethorphan hydrobromide and quinidine sulfate
SUBSTANCE NAME: DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE
TYPE: HUMAN PRESCRIPTION DRUG
PHARMA CLASS: Uncompetitive N-methyl-D-aspartate Receptor Antagonist [EPC],Sigma-1 Agonist [EPC],Uncompetitive NMDA Receptor Antagonists [MoA],Sigma-1 Receptor Agonists [MoA],Antiarrhythmic [EPC],Cytochrome P450 2D6 Inhibitor [EPC],Cytochrome P450 2D6 Inhibitors [MoA]
ROUTE: ORAL
DOSAGE FORM: CAPSULE, GELATIN COATED
MARKETING CATEGORY NAME: NDA
START MARKETING DATE: 2010-12-01
END MARKETING DATE: 0000-00-00


NUEDEXTA HUMAN PRESCRIPTION DRUG Details:

Item DescriptionNUEDEXTA from Avanir Pharmaceuticals, Inc.
LABELER NAME: Avanir Pharmaceuticals, Inc.
DEA SCHEDULE:
ACTIVE STRENGTH: 20; 10(mg/1; mg/1)
START MARKETING DATE: 2010-12-01
END MARKETING DATE: 0000-00-00
PRODUCT ID: 64597-301_1231729d-b4fe-4b91-a82d-c0d27b460262
PRODUCT NDC: 64597-301
APPLICATION NUMBER: NDA021879

Other DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
Avanir Pharmaceuticals, Inc.NUEDEXTA